6-{2-[2-(2-{2-[2-(2-methylsulfonylethoxy)ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-hexanoic acid ethyl ester

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-{2-[2-(2-{2-[2-(2-methylsulfonylethoxy)ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-hexanoic acid ethyl ester
• 英文别名: 6-{2-[2-(2-{2-[2-(2-methylsulfonylethoxy)ethoxyl]ethoxy}-ethoxy)-ethoxy]-ethoxy}-hexanoic acid ethyl ester；6-{2-[2-(2-{2-[2-(2-Methylsulfonylethoxy) ethoxy]ethoxy}-ethoxy)-ethoxy]-ethoxy}-hexanoic acid ethyl ester；ethyl 6-[2-[2-[2-[2-[2-(2-methylsulfonylethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]hexanoate
• 化学式: C₂₁H₄₂O₁₀S
• 分子量: 486.624
• InChiKey: VYPGBCXDVXAJPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  32
• 可旋转键数：
  26
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  124
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  6-{2-[2-(2-{2-[2-(2-methylsulfonylethoxy)ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-hexanoic acid ethyl ester 、 二乙二醇单甲醚 在 NaH 作用下， 以 甲醇 、 甲苯 为溶剂， 生成 6-(2-{2-[2-(2-{2-[2-(2-methoxyethoxy) ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-hexanoic acid ethyl ester
  参考文献：
  名称：

  Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith

  摘要：

  描述了包括胰岛素药物-寡聚体共轭物、脂肪酸成分和胆盐成分的制药组合物。胰岛素药物与寡聚体部分共价耦合。脂肪酸成分和胆盐成分以重量比在1:5至5:1之间存在。还提供了使用这种制药组合物治疗需要胰岛素缺乏的受试者的方法，以及提供这种制药组合物的方法。

  公开号：

  US06867183B2
• 作为产物：
  描述：

  6-{2-[2-(2-{2-[2-(2-hydroxyethoxy)-ethoxy]ethoxy}-ethoxy)-ethoxy]-ethoxy}-hexanoic acid ethyl ester 、 甲基磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以83%的产率得到6-{2-[2-(2-{2-[2-(2-methylsulfonylethoxy)ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-hexanoic acid ethyl ester
  参考文献：
  名称：

  Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

  摘要：

  披露了一种混合物，其中混合物中的每个共轭物包括与包含聚丙烯醚单元的寡聚物偶联的生长激素药物。

  公开号：

  US20030027995A1

文献信息

• Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
  申请人：——

  公开号：US20030069170A1

  公开（公告）日：2003-04-10

  Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating diseases in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

  描述了包括药物-寡聚物共轭物、脂肪酸成分和胆盐成分的药物组合物。药物以共价键连接到寡聚物基团上。脂肪酸成分和胆盐成分以1:5至5:1的重量比存在。还提供了利用这种药物组合物治疗需要此类治疗的受试者的方法，以及提供这种药物组合物的方法。
• Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
  申请人：——

  公开号：US20030229009A1

  公开（公告）日：2003-12-11

  Methods for synthesizing proinsulin polypeptides are described that include contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, and cleaving the one or more peptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. Methods of synthesizing proinsulin polypeptide-oligomer conjugates are also provided as are proinsulin polypeptide-oligomer conjugates. Methods of synthesizing C-peptide polypeptide-oligomer conjugates and other pro-polypeptide-oligomer conjugates are also provided.

  描述了合成前胰岛素多肽的方法，包括将包括胰岛素多肽和一个或多个肽段的前胰岛素多肽与一个寡聚体接触，这些肽段通过肽键结合，可以被切割以产生胰岛素多肽，条件足以将寡聚体与前胰岛素多肽的胰岛素多肽部分结合并提供前胰岛素多肽-寡聚体共轭物，并从前胰岛素多肽-寡聚体共轭物中切割一个或多个肽段，以提供胰岛素多肽-寡聚体共轭物。还提供了合成前胰岛素多肽-寡聚体共轭物的方法，以及前胰岛素多肽-寡聚体共轭物。还提供了合成C肽多肽-寡聚体共轭物和其他前多肽-寡聚体共轭物的方法。
• Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
  申请人：——

  公开号：US20030228275A1

  公开（公告）日：2003-12-11

  A non-polydispersed mixture of conjugates in which each conjugate in the mixture comprises a drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may be more effective at surviving an in vitro model of intestinal digestion than polydispersed mixtures of similar conjugates. The mixture may result in less inter-subject variability than polydispersed mixtures of similar conjugates.

  披露了一种非多分散混合物，其中混合物中的每个共轭物包括与包含聚乙二醇基团的寡聚物偶联的药物。该混合物可能表现出比类似共轭物的多分散混合物更高的体内活性。该混合物可能比类似共轭物的多分散混合物更有效地在体外模拟肠道消化模型中存活。该混合物可能导致比类似共轭物的多分散混合物更少的受试者间变异性。
• Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
  申请人：——

  公开号：US20030027748A1

  公开（公告）日：2003-02-06

  A mixture of conjugates in which each conjugate in the mixture comprises an insulin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may also be more effective at surviving an in vitro model of intestinal digestion than polydispersed mixtures of similar conjugates. The mixture may also result in less inter-subject variability than polydispersed mixtures of similar conjugates.

  披露了一种混合物，其中混合物中的每个共轭物包括与包含聚丙烯醚基团的寡聚体偶联的胰岛素药物。该混合物可能表现出比类似共轭物的多分散混合物更高的体内活性。该混合物在体外肠道消化模型中可能比类似共轭物的多分散混合物更有效地存活。该混合物可能导致比类似共轭物的多分散混合物更少的受试者间变异性。
• Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
  申请人：——

  公开号：US20030027995A1

  公开（公告）日：2003-02-06

  A mixture of conjugates in which each conjugate in the mixture comprises a growth hormone drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed.

  披露了一种混合物，其中混合物中的每个共轭物包括与包含聚丙烯醚单元的寡聚物偶联的生长激素药物。